WEBULL
WebtradeDownload

Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties

Simply Wall St · 2d ago
  • In the second quarter of 2026, Neuren Pharmaceuticals reported record DAYBUE net sales of US$125 million, its highest quarterly result since launch, driven by strong uptake of the new DAYBUE STIX powder formulation in the US and supported by positive regulatory progress in Europe.
  • This sales performance led Neuren to upgrade its full-year 2026 royalty income projections, underscoring how formulation innovation and advancing European approvals are influencing its revenue outlook.
  • We’ll now examine how the record DAYBUE sales and upgraded royalty outlook affect Neuren’s existing investment narrative and risk-reward balance.

The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Neuren Pharmaceuticals Investment Narrative Recap

To own Neuren today, you need to believe that DAYBUE can remain a durable, high-margin royalty stream while NNZ-2591 gradually broadens the portfolio. The record US$125 million DAYBUE quarter and higher 2026 royalty guidance appear to support the near term catalyst of DAYBUE adoption and European progress, but they do not remove the key risk of reliance on Acadia’s commercial performance and on U.S. payor settings, particularly Medicaid.

Among recent updates, the ongoing on-market share buyback of up to 6,350,631 shares stands out in light of DAYBUE’s record quarter. While the buyback was announced before this sales result, the combination of rising royalty expectations and active capital management is important when thinking about how Neuren may respond to stronger cash generation and how that interacts with future catalysts such as NNZ-2591 data and European DAYBUE launches.

Yet despite the strong DAYBUE result, investors should be aware that Neuren’s dependence on a single partner and product still...

Read the full narrative on Neuren Pharmaceuticals (it's free!)

Neuren Pharmaceuticals’ narrative projects A$166.7 million revenue and A$228.4 million earnings by 2028. This implies an 8.7% yearly revenue decline and an earnings increase of about A$79 million from A$149.1 million today.

Uncover how Neuren Pharmaceuticals' forecasts yield a A$23.45 fair value, a 8% upside to its current price.

Exploring Other Perspectives

ASX:NEU 1-Year Stock Price Chart
ASX:NEU 1-Year Stock Price Chart

Before this record quarter, the most optimistic analysts were already assuming around A$239.5 million revenue and A$140.4 million earnings by 2028, so you might now see their more upbeat view on faster approvals and expanding patient pools as less extreme, especially if you worry that heavy reliance on Acadia’s execution outside the U.S. could still cap how far this DAYBUE-led story can go.

Explore 5 other fair value estimates on Neuren Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Neuren Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
  • Our free Neuren Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neuren Pharmaceuticals' overall financial health at a glance.

No Opportunity In Neuren Pharmaceuticals?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.